Mironid announced a €39.9 million Series B round on August 7, 2026, securing an £8.4 million equity investment from the Scottish National Investment Bank to fund ADPKD drug development.
Mironid announced a €39.9 million Series B financing round on August 7, 2026.The round includes an £8.4 million equity investment from the Scottish National Investment Bank.
Mironid, a biopharmaceutical company headquartered in Glasgow, Scotland, disclosed that it closed a €39.9 million ($46 million) Series B funding round on August 7, 2026 [1]. The capital raise is intended to fund the clinical development of a small‑molecule therapeutic targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD), a hereditary kidney disorder with limited treatment options [1].
The financing round was led by existing backers and new participants. Key investors include the Scottish National Investment Bank (SNIB), which contributed an £8.4 million equity stake [2]; Roche Venture Fund; Epidarex Capital; Sofinnova Partners; BioGeneration Ventures; and the University of Strathclyde [2][3]. The collective commitment brings Mironid’s total Series B proceeds to €39.9 million, equivalent to approximately £34 million at prevailing exchange rates [2].
Funding Structure and Investor Participation
The Series B round combined equity and convertible‑note components, with SNIB’s £8.4 million representing a direct equity purchase [2]. Roche Venture Fund, a corporate venture arm of Roche, reaffirmed its support for Mironid’s pipeline, while Epidarex Capital and Sofinnova Partners contributed additional capital to meet the €39.9 million target [3]. BioGeneration Ventures and the University of Strathclyde each added strategic investment, underscoring the collaborative nature of the financing [2].
The investors’ participation reflects a broader trend of public‑private partnership in Scottish biotech. SNIB’s involvement aligns with its mandate to stimulate high‑growth sectors in Scotland, and the fund’s equity stake is the largest single contribution in the round [2]. The capital structure is designed to provide Mironid with sufficient runway to progress its lead candidate through pivotal clinical milestones [1][3].
Clinical Development Plan for ADPKD Mironid Secures €39.9 Million Series B to Advance ADPKD Therapy Mironid’s lead program is a small‑molecule inhibitor intended to slow cyst growth and preserve renal function in patients with ADPKD [1].
Mironid’s lead program is a small‑molecule inhibitor intended to slow cyst growth and preserve renal function in patients with ADPKD [1]. The Series B proceeds will fund pre‑clinical validation, manufacturing scale‑up, and the initiation of Phase 2 clinical trials slated for late 2026 [1][3]. The company has indicated that the funding will also support regulatory engagement with the European Medicines Agency and the U.S. Food and Drug Administration [2].
ADPKD affects approximately 12 million individuals worldwide and currently has limited disease‑modifying therapies [1]. Mironid’s candidate aims to address a therapeutic gap by targeting molecular pathways implicated in cystogenesis. Successful trial outcomes could position the company for subsequent Phase 3 studies and potential market entry, contingent on regulatory approval [3].
For patients and families affected by ADPKD, the funding announcement provides a concrete pathway toward a novel therapeutic option, with clinical trials expected to begin within the next twelve months [1]. Healthcare providers may anticipate enrollment opportunities for eligible patients once the Phase 2 protocol is finalized [3].
The infusion of €39.9 million reinforces Glasgow’s emerging biotech ecosystem, creating approximately 30–40 new research and development positions over the next two years, according to Mironid’s employment forecast [2]. The investment also signals confidence from both venture capital and public‑sector investors in Scotland’s capacity to develop advanced therapeutics [2][3].
Educational institutions, including the University of Strathclyde, stand to benefit from collaborative research agreements and potential technology transfer opportunities linked to the funded program [4]. The broader Scottish economy may experience ancillary growth through supply‑chain activities, laboratory services, and ancillary clinical trial infrastructure [2][4].
Key Facts
The infusion of €39.9 million reinforces Glasgow’s emerging biotech ecosystem, creating approximately 30–40 new research and development positions over the next two years, according to Mironid’s employment forecast [2].
What: Mironid raised €39.9 million in Series B financing to develop a treatment for ADPKD.
NewsNews
